New Alzheimer's drug faces uncertain regulatory path

Posted on AllSides November 30th, 2022
From The Left
Healthcare, Alzheimer's
Illustration: Aïda Amer/Axios

Researchers have at last found a drug that can slow the progression of Alzheimer's disease, according to clinical trial data presented last night. But regulators now have to weigh its relatively modest efficacy against safety risks.

What we're watching: The FDA will soon decide whether to approve Eisai's experimental drug lecanemab — and if so, for the general public or only certain patient populations.

Medicare will then have to decide whether to pay for it outside of clinical trials or to maintain restrictions it put in place when it considered a...

Read full story


AllSides Media Bias Rating: Lean Left
AllSides Media Bias Rating: Lean Left
See full bias rating for Axios
Learn about media bias

More News about Healthcare from the Left, Center and Right

From the Left

From the Center

From the Right